Insider Transactions in Q1 2021 at Acelrx Pharmaceuticals Inc (ACRX)
Insider Transaction List (Q1 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 30
2021
|
Marina Bozilenko |
BUY
Grant, award, or other acquisition
|
Direct |
15,000
+50.0%
|
-
|
|
Mar 03
2021
|
Vincent J. Angotti CHIEF EXECUTIVE OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
200,000
+23.9%
|
-
|
|
Mar 03
2021
|
Raffi Asadorian Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
68,750
+20.87%
|
-
|
|
Mar 03
2021
|
Badri N Dasu Chief Engineering Officer |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+19.63%
|
-
|
|
Mar 03
2021
|
Pamela P Palmer Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
68,750
+9.35%
|
-
|
|
Feb 11
2021
|
Vincent J. Angotti CHIEF EXECUTIVE OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
23,052
-5.11%
|
$46,104
$2.63 P/Share
|
|
Feb 11
2021
|
Pamela P Palmer Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
8,915
-1.48%
|
$17,830
$2.63 P/Share
|
|
Feb 11
2021
|
Badri N Dasu Chief Engineering Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
6,775
-4.47%
|
$13,550
$2.63 P/Share
|
|
Feb 11
2021
|
Raffi Asadorian Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
9,024
-4.69%
|
$18,048
$2.63 P/Share
|
|
Feb 06
2021
|
Vincent J. Angotti CHIEF EXECUTIVE OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
25,059
-5.26%
|
$50,118
$2.59 P/Share
|
|
Feb 06
2021
|
Pamela P Palmer Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
9,414
-1.54%
|
$18,828
$2.59 P/Share
|
|
Feb 06
2021
|
Badri N Dasu Chief Engineering Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
6,846
-4.32%
|
$13,692
$2.59 P/Share
|
|
Feb 06
2021
|
Raffi Asadorian Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
9,414
-4.67%
|
$18,828
$2.59 P/Share
|